Status:
COMPLETED
1 Year Trial Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Diabetic Nephropathies
Hypertension
Eligibility:
All Genders
30-80 years
Phase:
PHASE4
Brief Summary
The general aim of this study is to compare telmisartan 80 mg with valsartan 160 mg in hypertensive patients with type 2 diabetes and overt nephropathy with adjusted blood pressure beyond the target o...
Detailed Description
This is a randomised, double-blind, double-dummy, forced titration, multicentre, parallel group trial in patients with essential hypertension, diabetes mellitus type 2 and diabetic nephropathy. After...
Eligibility Criteria
Inclusion
- Type 2 diabetes mellitus
- Aged 30-70 years of age
- Hypertension at screening defined as:
- an average cuff systolic blood pressure \> 130 mmHg and/or diastolic blood pressure \>80 mmHg in untreated patients OR
- patients receiving antihypertensive therapy (i.e., medications specifically prescribed to treat hypertension)
- Overt nephropathy defined by 24 hour proteinuria \>= 900 mg and by serum creatinine below 265 mol/l (3.0 mg/dl)
Exclusion
- None
Key Trial Info
Start Date :
April 1 2003
Trial Type :
INTERVENTIONAL
End Date :
December 1 2005
Estimated Enrollment :
885 Patients enrolled
Trial Details
Trial ID
NCT00153023
Start Date
April 1 2003
End Date
December 1 2005
Last Update
November 13 2013
Active Locations (111)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital St. Anna
Brno, Czechia, 656 91
2
University Hospital Hradec Kralove
Hradec Králové, Czechia, 500 05
3
University Hospital Vihohrady
Prague, Czechia, 100 34
4
General University Hospital
Prague, Czechia, 128 08